Aptevo Therapeutics Inc.
APVO
$4.35
-$0.43-9.00%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -171.00K | 0.00 | -220.00K | -131.00K | -68.00K |
| Gross Profit | 171.00K | 0.00 | 220.00K | 131.00K | 68.00K |
| SG&A Expenses | 9.84M | 10.22M | 10.52M | 11.08M | 11.41M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 24.10M | 24.60M | 24.60M | 25.95M | 28.11M |
| Operating Income | -24.10M | -24.60M | -24.60M | -25.95M | -28.11M |
| Income Before Tax | -23.70M | -24.13M | -24.01M | -25.25M | -27.31M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -23.70 | -24.13 | -24.01 | -25.25 | -27.31 |
| Earnings from Discontinued Operations | -- | -- | 293.00K | 293.00K | 293.00K |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -23.70M | -24.13M | -23.72M | -24.95M | -27.02M |
| EBIT | -24.10M | -24.60M | -24.60M | -25.95M | -28.11M |
| EBITDA | -23.79M | -24.25M | -24.21M | -25.52M | -27.61M |
| EPS Basic | -600.36 | -512.48 | -357.84 | -- | -- |
| Normalized Basic EPS | -375.22 | -320.30 | -223.65 | -- | -- |
| EPS Diluted | -600.52 | -512.65 | -357.84 | -- | -- |
| Normalized Diluted EPS | -375.22 | -320.30 | -223.65 | -- | -- |
| Average Basic Shares Outstanding | 128.00K | 55.10K | 14.30K | -- | -- |
| Average Diluted Shares Outstanding | 128.00K | 55.10K | 14.30K | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |